Quick Answer
Ensysce Biosciences, Inc. reported Stockholders Equity of $3.21 million for the year ending 2025.
- Ensysce Biosciences, Inc. showed a decrease of -13.3% in Stockholders Equity from 2024 to 2025.
- This data is from Ensysce Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $5.00 million | Q1 2019: $5.00 million | Q2 2019: $5.00 million | Q3 2019: $5.00 million | Q4 2019: $5.00 million | Q1 2020: $4.52 million | Q2 2020: $5.00 million | Q3 2020: $5.00 million | Q1 2021: $1.89 million | Q2 2021: $5.41 million | Q3 2021: -$105.7 thousand | Q1 2022: $1.39 million | Q2 2022: -$491.6 thousand | Q3 2022: -$6.09 million | Q1 2023: $166.7 thousand | Q2 2023: $4.12 million | Q3 2023: $1.49 million | Q1 2024: $3.75 million | Q2 2024: $1.81 million | Q3 2024: $6.91 million | Q1 2025: $3.05 million | Q2 2025: $3.39 million | Q3 2025: $1.20 million.
- Over the full 9 years of available data (2017 to 2025), Ensysce Biosciences, Inc.'s Stockholders Equity has declined by 35.7%.
- Historical annual values: Fiscal year 2025: $3.21 million | Fiscal year 2024: $3.71 million | Fiscal year 2023: -$322.9 thousand | Fiscal year 2022: -$3.71 million | Fiscal year 2021: -$7.88 million | Fiscal year 2020: -$6.44 million | Fiscal year 2019: $5.00 million | Fiscal year 2018: $5.00 million | Fiscal year 2017: $5.00 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: